ST. JOSEPH, MO – (Mar. 22, 2010) – Boehringer Ingelheim Vetmedica, Inc., is partnering with National Cattlemen's Beef Association (NCBA) on a membership recruitment program this spring. The membership incentive program is for new members who join NCBA and its state affiliates.
Cattle producers who join NCBA as new members will receive a 500 mL bottle of CYDECTIN® (moxidectin) Pour-On from Boehringer Ingelheim Vetmedica, Inc. If this person also joins their state association as a new member, they will receive a second bottle of Cydectin Pour-On. An NCBA member that recruits a new member, also receives a bottle of Cydectin (limit one per recruiter).
"Boehringer Ingelheim Vetmedica, Inc. is pleased to continue the Cydectin product giveaway as part of the NCBA Top Hand Membership program through the spring of 2010," said Mike Randolph, Cydectin brand manager for Boehringer Ingelheim Vetmedica, Inc. "The real strength of the National Cattlemen's Beef Association is its membership. We are happy to support this program with a donation of Cydectin to new members."
The program will run through May 31, 2010, or while supplies last. The program has been offered nationwide through a direct mail campaign. Individual state associations are also promoting it to their membership.
For more information about the Top Hand membership recruiting program, contact the NCBA membership team at 866-233-3872.
Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, Mo.), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, Conn., and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and approximately 41,300 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2008, Boehringer Ingelheim posted net sales of US $17 billion (11.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.